An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients — STRIDE

Primary Mitochondrial Myopathy Clinical Trial

Official title:
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy

Status Completed

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with PMM.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04535609
Study type	Interventional
Source	Reneo Pharma Ltd
Contact
Status	Completed
Phase	Phase 2
Start date	May 21, 2021
Completion date	October 5, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03323749` - A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension	Phase 3
Terminated	`NCT04641962` - A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy	Phase 2
Terminated	`NCT03862846` - A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy	Phase 1
Terminated	`NCT05267574` - An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)	Phase 2/Phase 3